During This TCOYD® LIVE PLUS You will Learn:
- What are the latest important screening recommendations for heart failure in people with diabetes?
- How can Type 1 Diabetes be delayed, and why is screening first and second-degree relatives important?
- How can obesity be managed in 2024? What are important obesity measurements beyond body mass index?
- How can sustained weight management goals be achieved using new obesity medications, such as glucagon-like peptide-1 (GLP-1) agonists or dual glucose-dependent insulinotropic polypeptides (GIP)?
- How can you decrease the risk of hypoglycemia if you have diabetes? What are the most efficient ways to prevent and treat low blood sugar?
- What are three must-know facts about screening for fatty liver disease in people with diabetes?
- Emphasis on enabling health care providers to master diabetes technology, including CGM and hybrid closed loop systems.
- A closer look at bone health evaluation and treatment: What are the risk factors you must know to avoid a fracture?
New Standards of Care in Diabetes: What You and Your Doctor NEED To Know
…With Expert Endocrinologists (Living well with T1D!) Steven V. Edelman, MD; and Jeremy Pettus, MD
Did you know there is a universal guide that every healthcare provider refers to when treating their patients with diabetes? The 2024 American Diabetes Association Standards of Medical Care in Diabetes was just published and we are discussing key points that you as a person living with diabetes should know about!
Join us for a journey into the heart of diabetes care, where your knowledge meets action and empowerment. Let’s embrace health together!
LEARN EVEN MORE WITH TCOYD® LIVE PLUS
WATCH RELATED VIDEOS
READ RELATED ARTICLES
“What to Know about MASLD and MASH: Two Liver Conditions that Can Affect People with Diabetes”
READ ARTICLE
“Gain Nutrition Know-How to Successfully Take a Newer Injectable Type 2 Diabetes Medication”
READ ARTICLE
“I Screen You Screen…Why Everyone Should Be Screened for T1D”
READ ARTICLE
Xeris Pharmaceuticals, Inc., the maker of Gvoke HypoPen® (glucagon injection ), is dedicated to unlocking the potential of glucagon. We believe that our technology can have a profound impact on the lives of patients and their families. That’s why we are proud to be the first to develop liquid glucagon, but that’s just the beginning. We’re also studying how our formulation technology can impact patients with other conditions. We have a persistent drive to pursue solutions that have the potential to change lives. Get to know us and see how our technology is unlocking the potential of today’s medicines at xerispharma.com.
